Does oxcarbazepine warrant therapeutic drug monitoring? A critical review

Clinical Pharmacokinetics

Volumn 47, Issue 12, 2008, Pages 767-778

  Bring, Penny ^a,b   Ensom, Mary H H ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiepileptic drugs, pharmacokinetics; Drug monitoring; Epilepsy; Oxcarbazepine, pharmacokinetics

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; ETHINYLESTRADIOL; FELBAMATE; LAMOTRIGINE; LEVONORGESTREL; LICARBAZEPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID; ZONISAMIDE;

ANTICONVULSANT THERAPY; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL DECISION MAKING; CLINICAL TRIAL; CONFUSION; DIPLOPIA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; EPILEPSY; FATIGUE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPONATREMIA; LETHARGY; MASS SPECTROMETRY; NAUSEA; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; TREMOR; VERTIGO; VOMITING;

ALGORITHMS; ANTICONVULSANTS; CARBAMAZEPINE; DRUG MONITORING; HUMANS; HYDROXYLATION; SEIZURES;

EID: 56749139665     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/0003088-200847120-00002     Document Type: Review

References (66)

1. Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the "common" neurologic disorders? Neurology 2007; 68: 326-37
2. Duncan JS, Sander JW, Sisodiya SM, et al. Adult epilepsy. Lancet 2006; 367: 1087-100
3. Browne TR, Holmes GL. Epilepsy. N Engl J Med 2001; 344: 1145-51
4. Statistics Canada for the Division of Aging and Seniors. Canada's seniors: a growing population [online]. Available from URL: http://www.phac- aspc.gc.ca/seniors-aines/pubs/factoids/1999/pdf/entire_e.pdf [Accessed 2007 Dec 31]
5. U.S Census Bureau. US interim projections by age, sex, race, and Hispanic origin [online]. Available at: http://www.census.gov/ipc/www/usinterimproj/ [Accessed 2007 Dec 31]
6. Alves G, Figueiredo I, Castel-Branco M, et al. Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma. Biomed Chromatogr 2007; 21: 1127-34
7. Clinical Pharmacology. 2007: oxcarbazepine drug information [online]. Available from URL: http://www.clinicalpharmacology.com/apps/default.asp?.entry= 11&rNum=326 [Accessed 2007 Dec 31]
8. Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001; 15: 137-63
9. Neels HM, Sierens AC, Naelaerts K, et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004; 42: 1228-55
10. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006; 45: 1061-75
11. Trileptal® (oxcarbazepine): US prescribing information [online]. East Hanover (NJ): Novartis Pharmaceuticals Corporation, 2007 Aug [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/trileptal. pdf [Accessed 2008 Sep 19]
12. Flesch G. Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Invest 2004; 24: 185-203
13. Garnett WR, Anderson GD, Collins RJ. Antiepileptic drugs. In: Burton ME, Shaw LM, Schentag JJ, et al., editors. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. Philadelphia (PA): Lippincott Williams & Wilkins, 2006: 502-5
14. Breton H, Cociglio M, Bressolle F, et al. Liquid chromatrography- electrospray mass spectrometry determination of carbamazepine, oxcarbazepine and eight of their metabolites in human plasma. J Chromatogr B 2005; 828: 80-90
15. Glauser TA, Pippenger CE. Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy. Epilepsia 2000; 41 Suppl. 8: S6-S15
16. Flesch G, Tudor D, Souppart C, et al. Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects. Int J Clin Pharmacol Ther 2002; 40: 524-32
17. Armijo JA, Vega-Gil N, Shushtarian M, et al. 10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs. Ther Drug Monit 2005; 27: 199-204
18. Pucci V, Raggi MA. Analysis of antiepileptic drugs in biological fluids by means of electrokinetic chromatography. Electrophoresis 2005; 26: 767-82
19. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006; 45: 351-63
20. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit 2002; 24: 91-103
21. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000; 38: 191-204
22. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet 2007; 46: 209-19
23. Splinter MY. Pharmacokinetic properties on new antiepileptic drugs. J Pharm Pract 2005; 18: 444-60
24. May TW, Rambeck B, Salke-Kellermann A. Flucutations of 10-hydroxy-carbazepine during the day in epileptic patients. Acta Neurol Scand 1996; 93: 393-7
25. Bialer M. Extended-release formulations for the treatment of epilepsy. CNS Drugs 2007; 21: 765-74
26. Ensom MHH, Davis GA, Cropp CD, et al. Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes? Clin Pharmacokinet 1998; 34: 265-79
27. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy. Neurology 2004; 62: 1252-60
28. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy. Neurology 2004; 62: 1261-73
29. Kalis MM, Huff NA. Oxcarbazepine: an antiepileptic agent. Clin Ther 2001; 23: 680-700
30. Guay DRP. Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. Am J Geriatr Pharmacother 2003; 1: 18-37
31. Pratoomsri W, Yatham L, Bond DJ, et al. Oxcarbazepine in the treatment of bipolar disorder: a review. Can J Psychiatry 2006; 51: 540-5
32. Wallace SJ. Newer antiepileptic drugs: advantages and disadvantages. Brain Dev 2001; 23: 277-83
33. Van Parys J, Meinardi H. Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis. Epilepsy Res 1994; 19: 79-85
34. Bill P, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27: 195-204
35. Juenke JM, Brown PI, Urry FM, et al. Drug monitoring and toxicology: a procedure for the monitoring of oxcarbazepine metabolite by HPLC-UV. J Chromatogr Sci 2006; 44: 45-8
36. Greiner C, Haen E. Development of a simple column-switching high-performance liquid chromatography (HPLC) method for rapid and simultaneous routine serum monitoring of lamotrigine, oxcarbazepine, and 10- monohydroxycarbazepine (MHD). J Chromatogr B Analyt Technol Biomed Life Sci 2007; 854: 338-44
37. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25: 347-63
38. Pienimaki P, Fuchs S, Isojarvi J, et al. Improved detection and determination of carbamazepine and oxcarbazepine and their metabolites by high-performance liquid chromatography. J Chromatogr B 1995; 673: 97-105
39. Mazzucchelli I, Franco V, Fattore C, et al. A novel enantioselective microassay for the high-performance liquid chromatography determination of oxcarbazepine and its active metabolite monohydroxycarbazepine in the human plasma. Ther Drug Monit 2007; 29: 319-24
40. Kimiskidis V, Spanakis M, Niopas I, et al. Development and validation of a high performance liquid chromatographic method for the determination of oxcarbazepine and its main metabolites in human plasma and cerebrospinal fluid and its application to pharmacokinetic study. J Pharm Biomed Anal 2007; 43: 763-8
41. Contin M, Balboni M, Callegati E, et al. Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. J Chromatogr B 2005; 828: 113-7
42. Franceschi L, Furlanut M. A simple method to monitor plasma concentrations of oxcarbazepine, carbamazepine, their main metabolites and lamotrigine in epileptic patients. Pharmacol Res 2005; 51: 297-302
43. Mandrioli R, Ghedini N, Albani F, et al. Liquid chromatographic determination of oxcarbazepine and its metabolites in plasma of epileptic patients after solid-phase extraction. J Chromatogr B 2003; 783: 253-63
44. Levert H, Odou P, Robert H. LC determination of oxcarbazepine and its active metabolite in human serum. J Pharm Biomed Anal 2002; 28: 517-25
45. Souppart C, Decherf M, Humbert H, et al. Development of a high throughput 96-well plate sample preparation method for the determination of trileptal (oxcarbazepine) and its metabolites in human plasma. J Chromatogr B 2001; 762: 9-15
46. Vermeij T, Edelbroek P. Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 857: 40-6
47. Bugamelli F, Sabbioni C, Mandrioli R, et al. Simultaneous analysis of six antiepileptic drugs and two selected metabolites in human plasma by liquid chromatrography after solid-phase extraction. Anal Chim Acta 2002; 472: 1-10
48. Johannessen SI. Can pharmacokinetic variability be controlled for the patient's benefit? The place of TDM for new AEDs. Ther Drug Monit 2005; 27: 710-3
49. Borusiak P, Korn-Merker E, Holert N, et al. Oxcarbazepine in treatment of childhood epilepsy: a survey of 46 children and adolescents. J Epilepsy 1998; 11: 355-60
50. Tecoma E. Oxcarbazepine. Epilepsia 1999; 40 Suppl. 5: S37-46
51. Gonzalez-Esquivel DF, Ortega-Gavilan M, Alcantara-Lopez G, et al. Plasma level monitoring of oxcarbazepine in epileptic patients. Arch Med Res 2000; 31: 202-5
52. Friis M, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224-7
53. Tomson T, Johannessen SI. Therapeutic drug monitoring of the new antiepileptic drugs. Eur J Clin Pharmacol 2000; 55: 697-705
54. Parant F, Bossu H, Gagnieu M, et al. Cross-reactivity assessment of carbamazepine-10,11-epoxide, oxcarbazepine, and 10-hydroxy-carbazepine in two automated carbamazepine immunoassays: PETINIA and EMIT 2000. Ther Drug Monit 2003; 25: 41-5
55. Nedelman JR, Gasparini M, Sallas W, et al. Oxcarbazepine: an analysis of concentration-efficacy/safety relationships. Neurology 1999; 52: A524-5
56. Evans WE. General principles of clinical pharmacokinetics. In: Burton ME, Shaw LM, Schentag JJ, et al., editors. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2006: 3-29
57. Striano S, Striano P, Di Nocera P, et al. Relationship between serum monohydroxy-carbazepine concentrations and adverse effects in patient with epilepsy on high-dose oxcarbazepine therapy. Epilepsy Res 2006; 69: 170-6
58. Sabers A, Gram L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs 2000; 60: 23-33
59. May T, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 1999; 21: 175-81
60. Tartara A, Galimberti C, Manni R, et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydrox-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol 1993; 36: 366-8
61. Mckee P, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994; 37: 27-32
62. Mazzucchelli I, Onat FY, Ozkara C, et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 2006; 47: 504-9
63. Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology 2006; 67: 1497-9
64. Gareri P, Gravina T, Ferreri G, et al. Treatment of epilepsy in the elderly. Prog Neurobiol 1999; 58: 389-407
65. van Heiningen P, Eve M, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 50: 410-9
66. Commission on Antiepileptic Drugs. Guidelines for therapeutic monitoring of carbamazeantiepileptic drugs. Epilepsia 1993; 34: 585-7